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LETTERS TO THE EDITOR
Lung Adenocarcinoma
with Good Response to
Erlotinib after Gefitinib
Treatment Failure and
Acquired T790M
Mutation
To the Editor:
Epidermal growth factor tyrosine
kinase inhibitors (EGFR TKIs) are useful
in treating advanced non-small cell lung
cancer. So far, it remains unclear whether
EGFR-TKIs, namely gefitinib and erlo-
tinib, share cross-resistance, which, after
failure of one drug, excludes the use of the
other one. Here, we report a 72-year-old
woman, never smoker, who suffered from
dry cough for 3 months. In November
2004, the chest computed tomography
(CT) revealed left-side pleural effusion,
nodules at left upper lobe, and left lower
lobe (Figure 1A). Both cytology and cell
block of the pleural fluid showed adeno-
carcinoma with positive stain of thyroid
transcription factor-1. Epidermal growth
factor receptor (EGFR) sequencing
showed L858R mutation. Gefitinib was
prescribed as the first-line treatment for
the stage IV NSCLC. A chest CT per-
formed 3 months later showed partial re-
sponse. However, a follow-up chest CT
after another 3 months showed massive
left pleural effusion and progression of the
tumors (Figure 1B). The EGFR sequenc-
ing from the pleural fluid, in June 2005,
showed acquired T790M mutation in ad-
dition to the original L858R mutation.
Because of acquired resistance to ge-
fitinib, she received pleurodesis and sys-
temic chemotherapies, including gemcit-
abine, vinorelbine, and pemetrexed. A
chest CT in June 2006 disclosed disease
progression with accumulating left locu-
lated pleural effusion (Figure 1C). A re-
peated EGFR mutation analysis of the
pleural effusion still showed L858R plus
T790M. Erlotinib was given as the fifth-
line treatment from July 2006. The tumors
shrunk, and a partial response was
achieved (Figure 1D). The duration of
response to erlotinib lasted for 8 months
before progression.
Although both the reversible EGFR
TKIs share the same mechanism of drug
sensitivity, erlotinib seems to achieve
more survival benefit than gefitinib.1 After
a certain period of erlotinib or gefitinib
therapy, acquired resistance almost inevi-
tably developed, sometimes from a sec-
ondary EGFR T790M mutation. Tumors
with T790M mutation usually become
highly resistant to gefitinib or erlotinib.2
Yet, it is still inconclusive whether cross-
resistance is shared between these two
drugs. Viswanathan et al. reported five
patients with advanced NSCLC failed to
respond to erlotinib after progression on
gefitinib.3 Cho et al. showed that patients
responding to erlotinib after failure of ge-
fitinib had wild-type EGFR in tumors and
had stable disease while receiving ge-
fitinib.3 Chang et al. demonstrated a male
nonsmoker who had in-frame deletion of
exon 19.4 The patient had partial response
to erlotinib treatment after failure of ge-
fitinib treatment, but did not develop
T790M. Our patient developed acquired
T790M mutation of EGFR after 6 months
treatment of gefitinib with best partial re-
sponse, and still responded to erlotinib
therapy. Therefore, patients with T790M
EGFR mutation may still response to er-
lotinib after gefitinib treatment failure.
The frequency of this is unknown.
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FIGURE 1. Tumor response after treatment. A, the initial tumor when diagnosed.
B, six months after gefitinib treatment, the disease had progressed. Systemic che-
motherapy was given. C, the disease again progressed, erlotinib was prescribed. D,
five months after erlotinib treatment, the tumors had shrunk.
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Long-Lasting Complete
Remission with
Tyrosine Kinase
Inhibitor in
Bronchioloalveolar
Carcinoma with a so
far Unknown EGFR
Mutation
To the Editor:
The epidermal growth factor recep-
tor (EGFR) has been validated in several
preclinical studies as an important target
for novel molecular targeted therapy for
human carcinomas. Strategies to inhibit
EGFR include the use of blocking anti-
bodies and small-molecule tyrosine kinase
inhibitors. Gefitinib was approved in the
USA by the US Food and Drug Adminis-
tration in May 2003 for the treatment of
advanced non-small cell lung cancer
(NSCLC) in patients previously treated
with chemotherapy. However, a large
phase III randomized clinical trial did not
find a significant benefit from gefitinib,
when compared with placebo,1 whereas
other reports have described an associa-
tion between clinical response to gefitinib
and activating mutations of the EGFR ki-
nase domain.2,3
Han et al.4 performed an analysis
of EGFR mutation in a large series of
NSCLC cases reporting EGFR muta-
tions in 10% of the 375 adenocarcino-
mas, but none in the 454 squamous-cell
carcinomas examined; 26% of 86 bron-
chioloalveolar carcinomas (BAC) and
6% of 289 conventional adenocarcino-
mas harbored EGFR mutations. Two in-
dependent groups have provided evi-
dence of significantly increased survival
of NSCLC patients with mutated EGFR
in response to gefitinib.5,6
Here, we report the case of a 48-
year-old man, nonsmoker with meta-
static BAC of the lung that responded to
gefitinib. BAC of the right lung was
diagnosed in May 2003. After radical
pneumonectomy and hilar and mediasti-
num nodes excision (pT4N2M0), the pa-
tient was treated with four courses of
adjuvant chemotherapy with cisplatin-
gemcitabine.
One year later, the patient devel-
oped cough, bronchorrea, and dyspnea.
A total body computed tomography
(CT) scan showed a contralateral diffuse
relapse of disease, with ground glass
lesions in the entire left lung. Sputum
cytology confirmed BAC cells. The pa-
tient was treated with two courses of
cisplatin-gemcitabine. In May 2005, he
presented a serious dyspnea requiring per-
manent O2-delivery and a CT of the chest
showed disease progression (Figure 1A).
ECOG performance status was 4. On the
basis of the histologic diagnosis, non-
smoker, chemotherapy-refractory disease,
we decided to start treatment with gefitinib
(Iressa, Astra Zeneca, Pharmaceuticals,
Wilmington, DE) 250 mg/os/daily. The
patient’s respiratory status and general
condition improved over a few days, and a
CT scan showed a partial remission with
minimal residual disease and ground glass
areas still scattered in the pulmonary pa-
renchyma. In September 2006, a new CT
scan (Figure 1B) demonstrated a complete
remission, which is still long-lasting. In
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FIGURE 1. (A) Computed tomography (CT) chest scan at relapse of disease (May
2005); (B) CT chest scan after gefitinib therapy (September 2006); (C) Sequencing
of exon 20 shows two heterozygous mutations in tumor tissue DNA: a C to Y (C
or T) base-pair change (red arrow), resulting in a substitution of phenylalanine for
serine at position 784 (S784F); a G to R (A or G) base-pair change (black arrow),
resulting in a substitution of methionine for valine at position 786 (V786M); (D)
Sequencing of exon 20, derived from tumor tissue DNA, cloned fragment in plas-
mid: single mutation in homozygous shows a C to T base-pair change, resulting in
a substitution of phenylalanine for serine at position 784 (S784F), (E) Single muta-
tion in homozygous shows a G to A base-pair change, resulting in a substitution of
methionine for valine at position 786 (V786M).
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